Citadel Advisors
TARA icon

Citadel Advisors’s Protara Therapeutics TARA Stock Holding History

Citadel Advisors’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.71M Buy
1,232,365
+163,807
+15% +$779K ﹤0.01% 4827
2026
Q1 		$5.57M Buy
1,068,558
+167,017
+19% +$989K ﹤0.01% 4168
2025
Q4 		$4.81M Buy
901,541
+399,087
+79% +$2.22M ﹤0.01% 4345
2025
Q3 		$2.19M Buy
502,454
+89,923
+22% +$291K ﹤0.01% 5902
2025
Q2 		$1.25M Hold
412,531
– – ﹤0.01% 6612
2025
Q1 		$1.76M Sell
412,531
-615,003
-60% -$2.75M ﹤0.01% 5781
2024
Q4 		$5.43M Buy
1,027,534
+347,023
+51% +$1.12M ﹤0.01% 3829
2024
Q3 		$1.25M Buy
680,511
+15,139
+2% +$31.1K ﹤0.01% 6409
2024
Q2 		$1.38M Buy
665,372
+639,424
+2,464% +$1.87M ﹤0.01% 5990
2024
Q1 		$104K Sell
25,948
-12,087
-32% -$39K ﹤0.01% 11307
2023
Q4 		$71.1K Buy
38,035
+15,892
+72% +$23.4K ﹤0.01% 11369
2023
Q3 		$37K Buy
22,143
+12,135
+121% +$27.8K ﹤0.01% 12087
2023
Q2 		$23.9K Sell
10,008
-36,179
-78% -$107K ﹤0.01% 12576
2023
Q1 		$143K Buy
46,187
+31,339
+211% +$104K ﹤0.01% 10717
2022
Q4 		$39.8K Sell
14,848
-155,674
-91% -$491K ﹤0.01% 12423
2022
Q3 		$505K Sell
170,522
-72,049
-30% -$244K ﹤0.01% 8434
2022
Q2 		$711K Sell
242,571
-163,677
-40% -$599K ﹤0.01% 7834
2022
Q1 		$2.08M Sell
406,248
-22,118
-5% -$116K ﹤0.01% 6013
2021
Q4 		$2.89M Buy
428,366
+81,935
+24% +$565K ﹤0.01% 5417
2021
Q3 		$2.4M Buy
346,431
+4,410
+1% +$34.4K ﹤0.01% 5902
2021
Q2 		$3.33M Buy
342,021
+100,507
+42% +$1.14M ﹤0.01% 5352
2021
Q1 		$3.8M Buy
+241,514
New +$4.48M ﹤0.01% 4889
2020
Q1 		– Sell
-1,174
Closed -$19K – 10163
2019
Q4 		$19K Buy
+1,174
New +$13.5K ﹤0.01% 8946
2019
Q3 		– Sell
-1,051
Closed -$17K – 9741
2019
Q2 		$17K Buy
+1,051
New +$18.6K ﹤0.01% 8967
2018
Q2 		– Sell
-452
Closed -$45K – 9280
2018
Q1 		$45K Buy
+452
New +$41.1K ﹤0.01% 7954
2017
Q2 		– Sell
-312
Closed -$22K – 8047
2017
Q1 		$22K Buy
+312
New +$23.3K ﹤0.01% 7229

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Citadel Advisors's TARA Position: Q2 2026 in Review

Citadel Advisors increased its Protara Therapeutics (TARA) stake by 15% in Q2 2026, buying an estimated $779K and bringing the position to 1,232,365 shares worth $4.71M. The position accounts for ﹤0.01% of the portfolio, ranked #4827.

Citadel Advisors first reported a position in TARA in Q1 2017 and has held it in 26 quarters since. The position peaked at $5.57M in Q1 2026. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Citadel Advisors held 1,232,365 shares of Protara Therapeutics worth $4.71M as of Q2 2026.
  • Citadel Advisors bought 163,807 Protara Therapeutics shares in Q2 2026, an estimated $779K.
  • Protara Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4827 holding.
  • Citadel Advisors first reported a position in Protara Therapeutics in Q1 2017 and has held it in 26 quarters since.
  • Citadel Advisors's Protara Therapeutics position peaked at $5.57M in Q1 2026.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.